Baricitinib doses can be tapered without risk of relapse in most RA patients who achieve remission or low disease activity with the targeted synthetic DMARD, a study has shown. The first randomised controlled trial of tapering of the selective Janus kinase 1 and 2 inhibitor showed that it was feasible to move to a reduced ...
Study backs tapering of baricitinib in RA patients
By Michael Woodhead
11 Sep 2018